The discovery of biomarkers that can be used to determine success of cancer therapy or 3 resistance to it, at an early stage, presents a very complex problem. There are countless 4 biochemical pathways to be considered and the multifaceted characteristics of the cancer 5 cell have also to be taken into account; a cell that can largely evade the host's immune 6 responses and has mastered tissue invasion and anti-cancer drug resistance. Nevertheless 7 good places to start are the 'Hallmarks' of cancer proposed by Hanahan and Weinburg 8 (2000) , these include; evasion of apoptosis, self-sufficiency in growth signals, insensitivity to 9 anti-growth signals, tissue invasion and metastasis, limitless replicative potential and 2 MALDI-MSI is an advanced analytical tool that allows molecular profiling and imaging of 3 many classes of compounds including; proteins, peptides, lipids, drugs and many other 4 molecules directly from tissue sections. The use of this technique for the study of biological 5 tissue was first described by Caprioli et al. in 1997 [10] and it has been improved and 6 adapted for use in many other studies [11] [12] [13] [14] [15] [16] [17] . Briefly MALDI-MSI allows the acquisition of 7 multiple single mass spectra across the tissue section at a spatial resolution predefined by 8 the operator (typically 20-200m). These mass spectra are then combined together in order 9 to generate molecular maps or images which represent the distribution and the relative 10 abundance and/or intensity of a specific ion signal detected within the tissue section.
11
MALDI-MSI has been shown to be a powerful technique for direct protein analysis within 12 tissue sections and in tumour tissue samples, it has been used for discrimination between 13 tumour and non tumour regions with no requirement for predefined targets [18] [19] [20] [21] . Mice were injected sub-cutaneously in the flank with a 50l tumour cell suspension 10 containing 1x10 6 cells in serum-free medium. The cells employed in this study were from the 11 mouse fibrosarcoma cell line, VEGF120. This has been engineered to express only the 12 VEGF120 isoform [27] . Tumours were allowed to grow to approximately 500mm 3 , before 13 CA-4-P treatment (a single dose of 100mg/kg i.p). Mice were killed and tumours excised at 14 various time after treatment.
15
Experimental groups:
16
Controls (no treatment), n=6 (labelled tumour 1_1 -tumour 1_6), C-A4-P (0 hours after 17 treatment), n=6, (labelled tumour 2_1 -tumour 2_6), , C-A4-P (1/2 hour after treatment), n=6,
18
(labelled tumour 3_1 -tumour 3_6), C-A4-P (6 hours after treatment), n=6, (labelled tumour 19 4_1 -tumour 4_6), C-A4-P (24 hours after treatment) n=6, (labelled tumour 5_1 -tumour 5_6) 20 21 Tissue preparation -
22
Frozen tissue sections were cut to ~10µm, sections using a Leica CM3050 cryostat (Leica 23 Microsystems). The sections were then freeze thaw mounted on poly-lysine glass slides.
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Mounted slides were either used immediately or stored in an airtight tube @ -80°C for 1 subsequent use.
2
In situ tissue digestion -
3
The tissue samples were washed initially with 70% and 90% ethanol respectively for 1 4 minute then left to dry, after slides were immersed in Chloroform for 10 seconds. Prior to 5 matrix application In situ tissue digestion was performed with trypsin solution prepared (from 6 lyophilised trypsin) at 20µg/ml by addition of 50mM ammonium bicarbonate (NH 4 HC0 3 ) pH 7 8.12, containing 0.5% Octyl-α/ β-glucoside (OcGlc). Two automated systems were used 8 for trypsin application. The "Suncollect" (SunChrom, Friedrichsdorf, Germany) automatic 9 pneumatic sprayer was used to spray trypsin in a series of 5 layers employing flow rates of 10 2µl/min, 3µl/min and 4µl/min. The Portrait TM 630 Multispotter (Labcyte, Sunnyville CA) was 11 used to apply trypsin in a 200 µm -300 µm array of spots. The sections for MALDI-MS and 12 MALDI-MSI were incubated in a humidity chamber containing H 2 0 50%: Methanol 50% 13 overnight @ 37°C/ 5% C0 2.
14

Matrix deposition -
15
The matrix α-cyano-4-hydrocinnamic acid (CHCA) 5mg/ml (Suncollect) or 10mg/ml 16 Portrait TM ) and aniline in acetonitrile: water: TFA (1:1:0.1) was applied using the Suncollect 17 and Portrait TM 630 Multispotter as above with identical coordinate settings to trypsin 18 deposition to ensure conformity. Aniline was added to the CHCA solution in equimolar 19 amounts to the CHCA added (i.e. 5mg/ml CHCA matrix solution will contain 2.4µl 20 aniline). 21
Instrumentation -
22
Peptide mass fingerprints and images were acquired by MALDI-MS/MSI using an Applied 23 Biosystems Q-Star Pulsar i hybrid quadrupole time-of-flight mass spectrometer fitted with a 24 variable repetition rate Nd:YV0 4 laser set at 5 kHz . Image acquisition was performed using Page | 10 raster imaging mode at 150µm spatial resolution, Biomap 3.7.5.5 software was used for 1 image generation. To enable simple visual comparison between images all data was 2 normalised to m/z 877 (a peak arising from theCHCA matrix.) and intensity scales in the 3 BioMap software were all set to the same value. The potential for investigations into protein induction following drug treatment strategies are 3 phenomenal. Currently one major challenge is the management and analysis of the large 4 amounts of data generated. In each of the peptide mass fingerprints (Figures 1 and 3) , on 5 first inspection the spectrum seemed to be very noisy however this could be a signature of a 6 successful tryptic digestion. Therefore the many low abundance peptide signals contained in 7 the apparent noise could house significant proteins such as heat shock proteins and the like, Am. Soc. Mass Spectrom. 18, 1921 -1924 
